2026 Interim report
Filed with HKEX · Stock code 2566 · · 48 pages · English
Summary by 6ix AI
The report indicates a slight decrease in revenue compared to the previous year, while net profit showed a modest increase, attributed to various market and regulatory factors. Additionally, the report highlights the successful renewal of key products and their inclusion in the National Essential Drug List, enhancing their market accessibility.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. on 6ix
Earlier from Hangzhou Jiuyuan Genetic Biopharmaceutical
- Articles of association
- Poll results of the first extraordinary general meeting of 2026 held on Friday, September 18, 2026
- Next Day Disclosure Returns
- (Revised) Next Day Disclosure Returns
- List of directors and their roles and functions
Later from Hangzhou Jiuyuan Genetic Biopharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - JY54-2 Injection IND application formally accepted by cde
Follow Hangzhou Jiuyuan Genetic Biopharmaceutical into a list and get an email when it puts out news.
Follow Hangzhou Jiuyuan Genetic Biopharmaceutical